{
    "root": "303dda9b-8a02-68c8-e063-6294a90a2d5e",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Diclofenac Sodium",
    "value": "20250313",
    "ingredients": [
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "D&C RED NO. 27",
            "code": "2LRS185U6K"
        },
        {
            "name": "HYDROXYETHYL CELLULOSE (4000 MPA.S AT 1%)",
            "code": "ZYD53NBL45"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "ISOPROPYL ALCOHOL",
            "code": "ND2M416302"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673"
        },
        {
            "name": "DICLOFENAC SODIUM",
            "code": "QTG126297Q"
        }
    ],
    "indications": "Carefully consider the potential benefits and risks of diclofenac sodium extended-release tablets and other treatment options before deciding to use diclofenac sodium extended-release tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (\n \n  see\n                     \n                        WARNINGS,\n  \n   Gastrointestinal Bleeding, Ulceration, and Perforation\n                     ).\n\n \n                  Diclofenac Sodium Extended-release Tablets are indicated:\n                  \n                     for relief of the signs and symptoms of osteoarthritis\n                     for relief of the signs and symptoms of rheumatoid arthritis",
    "contraindications": "Carefully consider the potential benefits and risks of diclofenac sodium extended-release tablets and other treatment options before deciding to use diclofenac sodium extended-release tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see\n \n  \n                        WARNINGS\n                     ).\n\n \n                  After observing the response to initial therapy with diclofenac sodium extended-release tablets, the dose and frequency should be adjusted to suit an individual patient’s needs.\n                  For the relief of osteoarthritis, the recommended dosage is 100 mg daily.\n                  For the relief of rheumatoid arthritis, the recommended dosage is 100 mg daily. In the rare patient where diclofenac sodium extended-release tablets 100 mg/day is unsatisfactory, the dose may be increased to 100 mg twice a day if the benefits outweigh the clinical risks of increased side effects.\n                  Different formulations of diclofenac [diclofenac sodium enteric-coated tablets; diclofenac sodium extended-release tablets; diclofenac potassium immediate-release tablets] are not necessarily bioequivalent even if the milligram strength is the same.",
    "warningsAndPrecautions": "Diclofenac Sodium Extended-release Tablets are available as follows:\n                  100 mg – unscored, pink, round film coated tablets, engraved with “93” on one side and “1041” on the other side.\n                  NDC 68682-103-01 - Bottles of 100\n                  Store at room temperature 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].\n                  Protect from moisture.\n                  Dispense in tight container (USP). \n  \n                     \n                     Distributed by:\n                       Oceanside Pharmaceuticals, a division of \n    Bausch Health US, LLC \n    Bridgewater, NJ 08807 USA \n  \n                     \n                     Manufactured by:\n                       Bausch Health Companies Inc. \n    Steinbach, MB R5G 1Z7, Canada \n  \n                       © 2024 Bausch Health Companies Inc. or its affiliates \n  \n                       9493405 20005701\n\n \n                  Revised: 11/2024",
    "adverseReactions": "Diclofenac Sodium Extended-release Tablets are contraindicated in the following patients:\n                  \n                     Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac or any components of the drug product (\n  \n   see\n                        WARNINGS,\n  \n   Anaphylactic Reactions,\n  \n   Serious Skin Reactions).\n \n  \n                     History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients (\n  \n   see\n                        WARNINGS,\n  \n   Anaphylactic Reactions\n                        ;\n   \n    PRECAUTIONS, Exacerbation of Asthma Related to Aspirin Sensitivity\n                        ).\n \n  \n                     In the setting of coronary artery bypass graft (CABG) surgery (\n  \n   see\n   \n    WARNINGS,\n  \n   \n                        Cardiovascular Thrombotic Events)."
}